<SEC-DOCUMENT>0001019687-16-005773.txt : 20160407
<SEC-HEADER>0001019687-16-005773.hdr.sgml : 20160407
<ACCEPTANCE-DATETIME>20160407081722
ACCESSION NUMBER:		0001019687-16-005773
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160406
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160407
DATE AS OF CHANGE:		20160407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIMULATIONS PLUS INC
		CENTRAL INDEX KEY:			0001023459
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
		IRS NUMBER:				954595609
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32046
		FILM NUMBER:		161558791

	BUSINESS ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		STREET 2:		*
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
		BUSINESS PHONE:		661-723-7723

	MAIL ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>simulations_8k-040616.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED
STATES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">April 6, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">(Date
of the earliest event reported)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Simulations Plus, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%; text-align: center"><B>California</B></TD>
    <TD STYLE="width: 34%; text-align: center"><B>001-32046</B></TD>
    <TD STYLE="width: 33%; text-align: center"><B>95-4595609</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center">(State or other jurisdiction
of incorporation)</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">42505 10<SUP>th</SUP> Street West,
Lancaster, California 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">661-723-7723</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">Registrant's
telephone number, including area code</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b)) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item 8.01<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Events</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2016, Simulations Plus, Inc.,
a California corporation (the &quot;Company&quot;), issued a press release announcing that it has been awarded a $4.7 million,
five-year contract by a major research foundation that prefers to remain anonymous, contingent on satisfactory completion of project
milestones. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in this Current
Report on Form 8-K shall not be deemed to be &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the &quot;Exchange Act&quot;), or otherwise subject to the liabilities of that section, nor shall such information
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;),
or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in
this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current
Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K may contain
forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange Act. The forward-looking
statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of future performance and
are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate. Any forward-looking statements
in this Current Report on Form 8-K do not constitute guarantees of future performance and involve a number of factors that could
cause actual results to differ materially, including risks more fully described in our most recently filed Quarterly Report on
Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any forward-looking information contained
in this Current Report or with respect to the announcements described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in">99.1</TD><TD>Press release issued on April 6, 2016.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>SIMULATIONS PLUS, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Dated: April 7, 2016</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ John R. Kneisel</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">John R. Kneisel<BR>Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>simulations_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.gif" ALT="7D31DB5E-2666-46EF-BAF6-791B8297C46F[1]" STYLE="height: 38px; width: 213px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Further Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">42505 10<SUP>th</SUP> Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lancaster, CA 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><B>CONTACT</B>:</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><U>Simulations Plus Investor Relations</U></TD>
    <TD><U>Hayden IR</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Ms. Renee Bouche</TD>
    <TD>Mr. Cameron Donahue</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>661-723-7723</TD>
    <TD>651-653-1854</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><U>renee@simulations-plus.com</U></TD>
    <TD><U>cameron@haydenir.com</U></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Immediate Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 6, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Simulations Plus Signs 5-year Consulting
Agreement with Major Research Foundation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Project provides ~$4.7 million over
5 years to implement a<BR>
platform for global teams engaged in model-based drug development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Buffalo, NY, </B>April 6, 2016<B> &ndash;
</B>Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of modeling and simulation software for pharmaceutical discovery and
development, today announced that it has been awarded a $4.7 million, five-year contract by a major research foundation that prefers
to remain anonymous, contingent on satisfactory completion of project milestones. The agreement involves expansion and further
development of KIWI&trade;, a proprietary, cloud-based software platform to support modeling and simulation activities. Together,
Simulations Plus and the foundation plan to utilize the enhanced KIWI as an integral driver of the foundation&rsquo;s efforts to
support groundbreaking approaches to reducing the burden and accelerating progress toward eradication of underserved diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KIWI leverages the extensive business process
research that has been performed by the Buffalo, NY division of Simulations Plus (Cognigen Corporation), to support model-based
decision making across the research and development (R&amp;D) lifecycle. KIWI is used to efficiently organize, process, and communicate
modeling and simulation results. The enhancements to KIWI that will be made during this contract effort will provide a scaffold
with broad applicability to other therapeutic areas and will be available to industry and academic clients of KIWI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Ted Grasela, president of Simulations
Plus, said: &ldquo;Our collective vision for this initiative is to deploy an innovative, collaborative infrastructure, incorporated
into the KIWI platform, that will remove the barriers to communication amongst global team members. The platform will serve as
a framework for the interdisciplinary collaboration required to develop informative disease-drug models that make optimal use of
existing and emerging scientific research in underserved disease drug development. Ultimately, the goal is to reduce the risks
and cost of drug development and speed the delivery of new life-saving medicines.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are very excited about the opportunities
that arise from this project,&rdquo; Grasela continued. &ldquo;There is a remarkable, global community of scientists working through
this foundation&rsquo;s funding. This initiative provides much-needed support in terms of computer processing power and organizational
and communication tools for complex modeling and simulation projects. We look forward to working with the scientists, not-for-profit
organizations, and for-profit pharmaceutical and biotechnology companies who are partnering in the research areas funded by this
organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Walt Woltosz, chairman and chief executive
officer of Simulations Plus, Inc., said: &ldquo;The increasing use of modeling and simulation to support pharmaceutical R&amp;D
requires that we rethink business processes. This project demonstrates that the excellent work that Ted and our Buffalo division
have performed will be instrumental in reshaping the R&amp;D enterprise to maximize the value delivered by modeling and simulation
efforts.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simulations Plus, Inc., is a premier developer
of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by major
pharmaceutical and biotechnology companies worldwide. The company is a global leader focused on improving the ways scientists use
knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our innovations in integrating
new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into
our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation as well
as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more
information, visit our website at www.simulations-plus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor Statement Under the Private
Securities Litigation Reform Act of 1995</B> &ndash; With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and uncertainties. Words like &ldquo;believe,&rdquo;
&ldquo;expect&rdquo; and &ldquo;anticipate&rdquo; mean that these are our best estimates as of this writing, but that there can
be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ
significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to:
our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by
our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company,
and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with
the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#=A%0)@ '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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ML:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZMS)LZ?/GT"#%A0
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M7*K*O*I#'))VA[54%0M6P,Z-FH9X(R" #@DP D'>\UD#^<M<C4I8AG3H+5X
M P%R.0%&N""NY65;V!;R,+1Y: /HI($.:3""$"RR(9G"9_M,]"2$4 IB\970
M0#1H67]508L/AK"$5_#@!%3XEP#C(@FL"P $&, %_L*3!2#Q N]8C2!.,DJ
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M:[54+_56<;;O2K@%&=M63Y[^-,QE3,6(%:<I<;HRRVP ,%>!$0J!GJ>&  $
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M12+MMJY,"#8((23S]<$J"!I&8T<(N"76="X5A[B"]DR'H/X!@!]%V4"_MJ"
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MP3J5(X)Z&7"R15G;D=33)@TR%"M(]B,#^-04H(STA0S@%.<.A07N[@0,9OF
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MWP:J-!X^"&"/D0<P6,8R,,@O(S]^<@D:90 A! I&6Q^PH)&DQ&(B_8@<()+
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M\Z 5A2A/BU6YH!+UGT6-W"Z/ZDR+'G2G#.W?45_9-J"611Y*F<T#RNF1:7X
MDB#]*EBS*A&4^M%Z_5 +_R:K<[[N0<<P)>!D*=W5CW.U16_[5*I#=4G%.V:*
MJA/EHE^C6D"?WG*I"E5E[@+Z2J@>EJCLF:HM&<LV/%+6GW61F42E@H(*L"
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MQ>YUJ=G:[;R7V),"0Y5O,(,M&" $C<L<XKAE14?%H(XG-JB].X $%8"@!2
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M'H\:0(*@"S(  ;K ]:.<HQ8-NO\ML[S8C-&P#E3FM=Z)O!CC"X&[P#K&&&0
MX7-*NL# U@W&$(Z,Z1H0Z#BBH,8@KP*,FQX (PT*4^6GZ:$\HS#EJLYMB8"T
MN+@,;@PJD(Y<A*">H$QN?RH "KG 4JW3O.9Q'"'*V1 B#^BM#$R(V\K9@!<5
MX!UN?^UH@!!&5Y0"'&YPO;N$:4A8$/@]+GT%9!U"Y/>_N^GP?Y&B$:-XJ$-*
MP>L>FI'9AF*##_V "20F<4U0.M2A"ZQL71U8&@8$DB;3Z*<FP<. 7""TH08X
M3P R($I,M/>FFD&10S5YFA4T( \(*3$H7]+/AL#B/.Q4A '8$LP]VD%'^(&
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0(1[Q3=<-TU"6^,4U'1  .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
